• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法布瑞病患者骨矿物质密度的调查及酶替代疗法的变化。

Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease.

机构信息

Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan.

Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan.

出版信息

Mol Genet Metab. 2023 Aug;139(4):107634. doi: 10.1016/j.ymgme.2023.107634. Epub 2023 Jun 27.

DOI:10.1016/j.ymgme.2023.107634
PMID:37406430
Abstract

BACKGROUND

Fabry disease (FD) is an inherited disorder that causes organ dysfunction. However, only a few studies have reported on bone mineral density (BMD) in FD patients, and the relationship between BMD and clinical factors such as globotriaosylsphingosine (lyso-Gb3) remains unclear. Therefore, the current study sought to investigate BMD in FD patients, the relationship between BMD and lyso-Gb3, and the effects of enzyme replacement therapy (ERT) on changes in BMD and lyso-Gb3.

METHODS

This single-center, observational study included 15 patients who visited our facility for FD between January 2008 and June 2021. We assessed BMD and clinical characteristics in study patients, including plasma lyso-Gb3 levels, and examined the relationship between BMD and plasma lyso-Gb3 levels, and changes in BMD after starting ERT.

RESULTS

Male patients' BMD had reduced, whereas female patients' BMD was preserved. Male patients had significantly higher plasma lyso-Gb3 levels than female patients. Moreover, plasma lyso-Gb3 levels were found to be significantly related to the lumbar spine and femoral BMD. These were strongly linked with plasma lyso-Gb3 levels in male patients, whereas no strong link was observed in female patients. Furthermore, BMD significantly increased only in male patients although plasma lyso-Gb3 levels significantly decreased by ERT in all patients.

CONCLUSION

BMD decreased possibly due to Gb3 accumulation, and ERT could increase BMD in male FD patients.

摘要

背景

法布瑞病(FD)是一种遗传性疾病,可导致器官功能障碍。然而,仅有少数研究报道了 FD 患者的骨密度(BMD),并且 BMD 与神经酰胺三己糖苷(lyso-Gb3)等临床因素之间的关系尚不清楚。因此,本研究旨在探讨 FD 患者的 BMD、BMD 与 lyso-Gb3 的关系,以及酶替代疗法(ERT)对 BMD 和 lyso-Gb3 变化的影响。

方法

这是一项单中心、观察性研究,纳入了 2008 年 1 月至 2021 年 6 月期间在我院就诊的 15 例 FD 患者。我们评估了研究患者的 BMD 和临床特征,包括血浆 lyso-Gb3 水平,并检查了 BMD 与血浆 lyso-Gb3 水平之间的关系,以及 ERT 开始后 BMD 的变化。

结果

男性患者的 BMD 降低,而女性患者的 BMD 保持不变。男性患者的血浆 lyso-Gb3 水平显著高于女性患者。此外,血浆 lyso-Gb3 水平与腰椎和股骨 BMD 显著相关。在男性患者中,这些与血浆 lyso-Gb3 水平密切相关,而在女性患者中则没有明显关联。此外,尽管所有患者的血浆 lyso-Gb3 水平均显著降低,但仅在男性患者中 BMD 显著增加。

结论

BMD 可能由于 Gb3 积累而降低,ERT 可增加男性 FD 患者的 BMD。

相似文献

1
Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease.法布瑞病患者骨矿物质密度的调查及酶替代疗法的变化。
Mol Genet Metab. 2023 Aug;139(4):107634. doi: 10.1016/j.ymgme.2023.107634. Epub 2023 Jun 27.
2
Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).对于携带中国热点突变(IVS4+919G>A)的晚发型法布里病患者,球三糖基鞘氨醇(溶血型Gb3)可能不是监测酶替代疗法长期治疗效果的可靠标志物。
Orphanet J Rare Dis. 2014 Jul 22;9:111. doi: 10.1186/s13023-014-0111-y.
3
Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.组织和血浆神经酰胺三己糖苷脂可以作为评估法布雷病酶替代治疗的生物标志物。
Biochem Biophys Res Commun. 2010 Sep 3;399(4):716-20. doi: 10.1016/j.bbrc.2010.08.006. Epub 2010 Aug 6.
4
Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.阿加糖酶α对36例初治法布里病患者进行酶替代治疗的疗效与安全性。
BMC Pharmacol Toxicol. 2017 Jun 7;18(1):43. doi: 10.1186/s40360-017-0152-7.
5
Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.血浆溶血型Gb3:一种在酶替代疗法期间监测法布里病患者的生物标志物。
Clin Exp Nephrol. 2018 Aug;22(4):843-849. doi: 10.1007/s10157-017-1525-3. Epub 2017 Dec 29.
6
Plasma globotriaosylsphingosine as a biomarker of Fabry disease.血浆神经酰胺三己糖苷作为法布雷病的生物标志物。
Mol Genet Metab. 2010 Jul;100(3):257-61. doi: 10.1016/j.ymgme.2010.03.020. Epub 2010 Apr 1.
7
A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.一种用于定量血浆神经酰胺三己糖苷的简单方法:在法布雷病中的应用。
Mol Genet Metab. 2017 Sep;122(1-2):121-125. doi: 10.1016/j.ymgme.2017.08.004. Epub 2017 Aug 19.
8
Globotriaosylsphingosine (Lyso-Gb) as a biomarker for cardiac variant (N215S) Fabry disease.神经酰胺三己糖苷(Lyso-Gb)作为心脏变异型(N215S)法布雷病的生物标志物。
J Inherit Metab Dis. 2018 Mar;41(2):239-247. doi: 10.1007/s10545-017-0127-2. Epub 2018 Jan 2.
9
Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients.各种表型法布雷患者体液中积累的神经酰胺糖苷脂同型物和神经酰胺糖苷脂异构体的特征。
Intern Med. 2024 Jun 1;63(11):1531-1537. doi: 10.2169/internalmedicine.2493-23. Epub 2023 Oct 20.
10
Globotriaosylsphingosine (lyso-Gb) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort.血浆和尿液中的神经酰胺三己糖苷(lyso-Gb)及其类似物与法布里病患者的长期治疗和基因型的相关性:一项丹麦全国女性队列研究。
J Med Genet. 2021 Oct;58(10):692-700. doi: 10.1136/jmedgenet-2020-107162. Epub 2020 Sep 22.

引用本文的文献

1
Assessing osteopenia and osteoporosis with dual-energy x-ray absorptiometry studies in Fabry disease.在法布里病中使用双能X线吸收测定法评估骨质减少和骨质疏松症。
Orphanet J Rare Dis. 2025 Apr 30;20(1):206. doi: 10.1186/s13023-025-03601-x.
2
Bilateral avascular necrosis: A rare complication of Fabry disease.双侧缺血性坏死:法布里病的一种罕见并发症。
Mol Genet Metab Rep. 2025 Apr 12;43:101219. doi: 10.1016/j.ymgmr.2025.101219. eCollection 2025 Jun.
3
Decreased trabecular bone score in patients affected by Fabry disease.法布里病患者的小梁骨评分降低。
J Endocrinol Invest. 2025 Jan;48(1):121-130. doi: 10.1007/s40618-024-02427-x. Epub 2024 Oct 3.
4
The Effect of Fabry Disease Therapy on Bone Mineral Density.法布里病治疗对骨密度的影响。
Diseases. 2024 May 13;12(5):102. doi: 10.3390/diseases12050102.
5
Increased Soluble Interleukin 6 Receptors in Fabry Disease.法布里病中可溶性白细胞介素6受体增加。
J Clin Med. 2023 Dec 29;13(1):218. doi: 10.3390/jcm13010218.